News | January 23, 2026
Akeso’s novel AS drug Gumokimab accepted for review by China’s drug regulator
This marks the second indication for which gumokimab has gained NDA review acceptance
This marks the second indication for which gumokimab has gained NDA review acceptance
The registrations grant Neurizon exclusive rights to use and defend its brand across its core operating regions
The study evaluated patients with stage III/IV melanoma after complete tumor resection
Sofetabart mipitecan is a novel folate receptor alpha (FR?) antibody-drug conjugate (ADC) leveraging proprietary linker technology and an exatecan payload to target tumor cells
Myqorzo, a selective small-molecule cardiac myosin inhibitor, is designed to improve functional capacity and relieve symptoms in oHCM
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
The randomized, double-blind, placebo-controlled Phase 2b VITAL trial enrolled 91 patients with newly diagnosed Stage IIIb–IV epithelial ovarian cancer
Treatment typically requires frequent injections directly into the eye—an ongoing burden for patients and health systems alike
LOTTE Biologics will provide advanced manufacturing services for monoclonal antibody intermediates and their conjugates
ATEC secures exclusive U.S. commercial rights to Theradaptive’s OsteoAdapt osteoinductive bone graft, currently in clinical trials for spinal and dental applications
Subscribe To Our Newsletter & Stay Updated
